{"entity":{"id":"nct06190886","kind":"trial","name":"A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors","aka":[],"tldr":"A phase 1 trial of PTX-912 run by Proviva Therapeutics, Inc., now recruiting.","summary":"A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06190886 by Proviva Therapeutics, Inc., with 26 participants planned, started 2024-06-11, primary completion expected 2026-05-14. Conditions recorded: Advanced Cancer, Solid Tumor, Metastatic Cancer. Interventions recorded: PTX-912.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06190886","url":"https://clinicaltrials.gov/study/NCT06190886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ptx-912"],"companies":["proviva-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06190886","phase":"1","setting":"A First-in-human (FIH), Multicenter, Open-Label, Phase Ia (Dose Escalation)/Phase Ib (Dose Expansion) Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors","sponsor":"Proviva Therapeutics, Inc.","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06190886/","neighbours":{"drug":[{"id":"ptx-912","kind":"drug","name":"PTX-912","route":"/drugs/ptx-912/"}],"company":[{"id":"proviva-therapeutics","kind":"company","name":"Proviva Therapeutics","route":"/companies/proviva-therapeutics/"}]}}